2020
The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda
Loflin MJE, Kiluk BD, Huestis MA, Aklin WM, Budney AJ, Carroll KM, D'Souza DC, Dworkin RH, Gray KM, Hasin DS, Lee DC, Le Foll B, Levin FR, Lile JA, Mason BJ, McRae-Clark AL, Montoya I, Peters EN, Ramey T, Turk DC, Vandrey R, Weiss RD, Strain EC. The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug And Alcohol Dependence 2020, 212: 107993. PMID: 32360455, PMCID: PMC7293929, DOI: 10.1016/j.drugalcdep.2020.107993.Peer-Reviewed Original ResearchConceptsClinical outcome assessmentCannabis use disorderClinical trialsOutcome assessmentForms of cannabisCannabis-related harmsCannabis reductionPrimary outcomeFunctional outcomeInterpretation of outcomesClinical endpointsNew pharmacotherapiesPsychomotor impairmentOutcome measuresSelf-report assessmentsDiagnostic criteriaUse disordersOptimal durationCannabis useStudy designBiologic assaysTrialsOptimal outcomesLack of consensusCannabis
2017
Initial validation of a proxy indicator of functioning as a potential tool for establishing a clinically meaningful cocaine use outcome
Kiluk BD, Babuscio TA, Nich C, Carroll KM. Initial validation of a proxy indicator of functioning as a potential tool for establishing a clinically meaningful cocaine use outcome. Drug And Alcohol Dependence 2017, 179: 400-407. PMID: 28858744, PMCID: PMC5611843, DOI: 10.1016/j.drugalcdep.2017.07.020.Peer-Reviewed Original Research